Ocular Therapeutix reported Q1 results on May 5 that landed below expectations on every line — EPS of -$0.40 missed the -$0.33 estimate, and revenue of $10.8 million trailed the $12.6 million consensus. The stock slipped just 0.6% on the day, suggesting the miss was absorbed quickly, but the week's more interesting story is what sits behind the headline: shorts have been rebuilding steadily into the print, options traders have swung sharply bullish, and a second earnings event is scheduled for May 8.
Short interest is the clearest tension point right now. At 12.0% of the free float, it has risen roughly 9% over the past month — a steady build, not a spike. The week-on-week gain of about 1.2% continued a trend that began in early April, when SI climbed from around 9.7% of float to the current level. Days to cover from the most recent FINRA settlement stand at nearly seven, meaning any rapid covering would require meaningful buying pressure. Despite this, the borrow market itself remains relaxed. Cost to borrow has trended down roughly 8% from a month ago, running near 0.46% — essentially negligible. Availability has tightened slightly this week, with utilization climbing from 22% to 24%, but both measures remain well below stress thresholds; the 52-week utilization peak was 36.6%, well above current levels. Shorts are present and growing, but the borrow market is not squeezed.
Options positioning tells the opposite story. The put/call ratio has collapsed to 0.19, far below its 20-day average of 0.32 and near the 52-week low of 0.11. That means call volume dominates heavily — options traders are positioned for upside, not downside protection. The contrast with the short interest trend is sharp. Short sellers have added positions through April, while the options market has swung toward calls at the same time the stock climbed 14% over the past month to $9.71. The ORTEX short score of 60.5 has crept higher all week from 59.1, flagging a modestly elevated bearish positioning score, but well below extreme territory.
The Street remains firmly constructive despite the Q1 miss. RBC Capital reiterated its Outperform rating and $30 target on May 6 — the most recent action from a coverage firm. The consensus across seven buy-rated analysts carries a mean price target of $26, implying roughly 168% upside from current levels. That wide gap between target and price reflects the binary nature of the AXPAXLI story: the pipeline asset for wet AMD has shown strong phase 3 data, with the company citing superior results versus standard-of-care aflibercept 2mg and potential 12-month durability. The bull case hinges entirely on FDA approval. The bear case — also well-articulated — centres on regulatory risk from a single-study approval pathway and a competitive wet AMD market that already houses entrenched biologics. No analysts have cut ratings, and Clear Street raised its target from $21 to $28 in early March, but the stock is still trading at a steep discount to even the lowest published target of $18.
Institutional ownership adds some colour to the long side. BlackRock added over 5 million shares in Q1, lifting its stake to 7.2% of shares. Vanguard added 2.4 million shares in the same period, taking its position to 5.3%. Deep Track Capital added 2 million shares in the February period, bringing its holding to 4.6%. Those three names together added roughly 9.5 million shares in the most recent reporting windows — a meaningful accumulation as the stock traded below $10. Insider activity, by contrast, leaned the other way in February, with the CEO, CFO, and several C-suite officers all selling shares around the $8–$9 level. One director — Richard Lindstrom — purchased 60,229 shares at $7.66 in a move that stood apart from the cluster of executive sales.
The previous two earnings reactions give a mixed read. The March 6 release saw the stock drop 3.8% on day one and slide 15.2% over the following five sessions. The February 5 print triggered a 7.1% gain on the day and a further 6.0% gain over five sessions. With Q1 results now out and already digested with a muted reaction, the focus shifts to the May 8 event — whether that is an earnings call, an investor day, or a regulatory update will determine whether the divergence between short rebuilding and call-dominated options positioning resolves in either direction.
See the live data behind this article on ORTEX.
Open OCUL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
